- Home
- ABSI vs AUTL Comparison
ABSI vs AUTL Comparison
Compare ABSI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- AUTL
- Stock Information
- Founded
- ABSI 2011
- AUTL 2014
- Country
- ABSI United States
- AUTL United Kingdom
- Employees
- ABSI N/A
- AUTL 647
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABSI Health Care
- AUTL Health Care
- Exchange
- ABSI Nasdaq
- AUTL Nasdaq
- Market Cap
- ABSI 353.8M
- AUTL 359.3M
- IPO Year
- ABSI 2021
- AUTL 2018
- Fundamental
- Price
- ABSI $2.75
- AUTL $1.32
- Analyst Decision
- ABSI Strong Buy
- AUTL Strong Buy
- Analyst Count
- ABSI 5
- AUTL 5
- Target Price
- ABSI $8.40
- AUTL $9.32
- AVG Volume (30 Days)
- ABSI 2.5M
- AUTL 2.4M
- Earning Date
- ABSI 05-13-2025
- AUTL 05-08-2025
- Dividend Yield
- ABSI N/A
- AUTL N/A
- EPS Growth
- ABSI N/A
- AUTL N/A
- EPS
- ABSI N/A
- AUTL N/A
- Revenue
- ABSI $4,534,000.00
- AUTL $9,011,000.00
- Revenue This Year
- ABSI $158.58
- AUTL $277.74
- Revenue Next Year
- ABSI $93.12
- AUTL $221.89
- P/E Ratio
- ABSI N/A
- AUTL N/A
- Revenue Growth
- ABSI N/A
- AUTL N/A
- 52 Week Low
- ABSI $2.01
- AUTL $1.11
- 52 Week High
- ABSI $6.33
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- ABSI 42.92
- AUTL 45.63
- Support Level
- ABSI $2.85
- AUTL $1.15
- Resistance Level
- ABSI $2.94
- AUTL $1.44
- Average True Range (ATR)
- ABSI 0.19
- AUTL 0.14
- MACD
- ABSI -0.03
- AUTL 0.01
- Stochastic Oscillator
- ABSI 14.13
- AUTL 29.82
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.